ArticleNutrients2026
Combined HMOs and α-MFGM Ameliorate LPS-Induced Intestinal Mucosal and Systemic Immune Dysfunction via Modulation of Gut Microbiota.
Article in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe intestine functions as the body's primary immune barrier, playing a vital role in host defense against pathogens. Human milk oligosaccharides (HMOs: 2'-fucosyllactose and lacto-N-neotetraose) and α-milk fat globule membrane (α-MFGM) are key bioactive components in human milk known to regulate intestinal immunity. Although their individual benefits have been reported, the potential combined effects of their combined use on intestinal mucosal and systemic immune function remain poorly understood.
methodsTo address this, we established a lipopolysaccharide (LPS)-induced intestinal injury model in BALB/c mice. The animals were randomly divided into five groups: normal control, LPS model control, α-MFGM alone, HMOs alone (2'-FL + LNnT), and combined α-MFGM + HMOs intervention. After 15 days of oral gavage, colonic histopathology, intestinal barrier integrity, immune organ indices, serum inflammatory cytokine levels, immune cell subsets, and gut microbiota composition were comprehensively evaluated.
resultsCombined supplementation with HMOs and α-MFGM effectively alleviated colonic pathological damage, increased goblet cell numbers and mucus secretion, enhanced sIgA expression, and reduced serum DAO and D-lactate levels, indicating restored intestinal barrier function. It also balanced spleen and thymus indices, suppressed pro-inflammatory TNF-α/IL-6 production, elevated anti-inflammatory IL-10/IL-22 levels, and corrected the LPS-induced Th1/Th2 and Th17/Treg imbalances. Moreover, the combined intervention remodeled the gut microbiota by enriching beneficial
conclusionsThese findings demonstrate that HMOs and α-MFGM exert combined protective effects against LPS-induced intestinal immune dysfunction through modulation of the gut microbiota and its metabolic products, providing a scientific foundation for optimizing early-life nutritional strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.